Company Fresenius Kabi Oncology Ltd
Equities
INE575G01010
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- INR | - |
2016 | AstraZeneca sells rights to anaesthetics for up to $770 million | RE |
2015 | Fresenius SE KGaA : Kabi sells German oncology compounding business | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 18-06-30 | |
Rahul Sharma
DFI | Director of Finance/CFO | - | - |
Maria Gobbi
CHM | Chairman | - | 14-11-12 |
Director/Board Member | - | 07-07-20 | |
Director/Board Member | 63 | 08-08-10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 08-08-10 | |
Director/Board Member | - | 07-07-20 | |
Maria Gobbi
CHM | Chairman | - | 14-11-12 |
Director/Board Member | - | 19-05-09 | |
Chief Executive Officer | - | 18-06-30 | |
Maurizio Villa
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 480,427,326 | 0 | 0 | - |
Company contact information
Fresenius Kabi Oncology Ltd.
Echelon Institutional Area Plot No-11, Sector-32
122001, Gurgaon
+91 12 4488 5000
http://www.fresenius-kabi-oncology.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- Stock
- Company Fresenius Kabi Oncology Ltd